Currently, the CodeBreaK201 is investigating sotorasib 960 mg daily versus 240 mg daily as first-line treatment in patients with KRASG12C-mutated NSCLC with a PD-L1 tumour proportion score of <1% and/or presence of a STK11 mutation (NCT04933695). Here, CD274 is linked to neoplasm.